- Home
- IVZ vs ROIV Comparison
IVZ vs ROIV Comparison
Compare IVZ & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVZ
- ROIV
- Stock Information
- Founded
- IVZ 1935
- ROIV 2014
- Country
- IVZ United States
- ROIV United Kingdom
- Employees
- IVZ N/A
- ROIV N/A
- Industry
- IVZ Investment Managers
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- IVZ Finance
- ROIV Health Care
- Exchange
- IVZ Nasdaq
- ROIV Nasdaq
- Market Cap
- IVZ 7.0B
- ROIV 7.8B
- IPO Year
- IVZ 1995
- ROIV N/A
- Fundamental
- Price
- IVZ $21.22
- ROIV $11.50
- Analyst Decision
- IVZ Hold
- ROIV Buy
- Analyst Count
- IVZ 16
- ROIV 3
- Target Price
- IVZ $18.48
- ROIV $15.25
- AVG Volume (30 Days)
- IVZ 7.5M
- ROIV 6.9M
- Earning Date
- IVZ 07-22-2025
- ROIV 08-07-2025
- Dividend Yield
- IVZ 3.95%
- ROIV N/A
- EPS Growth
- IVZ N/A
- ROIV N/A
- EPS
- IVZ 1.24
- ROIV N/A
- Revenue
- IVZ $6,153,100,000.00
- ROIV $29,053,000.00
- Revenue This Year
- IVZ N/A
- ROIV $3.28
- Revenue Next Year
- IVZ $3.97
- ROIV $156.84
- P/E Ratio
- IVZ $17.17
- ROIV N/A
- Revenue Growth
- IVZ 6.02
- ROIV N/A
- 52 Week Low
- IVZ $11.60
- ROIV $8.73
- 52 Week High
- IVZ $21.69
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- IVZ 86.51
- ROIV 54.28
- Support Level
- IVZ $16.49
- ROIV $11.38
- Resistance Level
- IVZ $17.53
- ROIV $11.74
- Average True Range (ATR)
- IVZ 0.63
- ROIV 0.27
- MACD
- IVZ 0.39
- ROIV 0.02
- Stochastic Oscillator
- IVZ 88.77
- ROIV 73.95
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.